Loading
A Chinese study of about 12,000 people testing whether blood proteins and DNA methylation together find several cancers early.
PRESCIENT (NCT04822792) is an observational study sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences with Guangzhou Burning Rock Dx Co., Ltd. It aims to detect cancers early with combined serum protein and cell-free DNA methylation assays, with blood RNA markers also evaluated.
The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 2 June 2021), with an estimated 11,879 participants, a start on 23 March 2021 and primary completion expected on 31 March 2023.
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/